TapImmune Inc. Stock OTC Bulletin Board
Stocks
TPIV
US8760334081
Biotechnology & Medical Research
| Market Cap | 19.01M 16.47M 15.57M 14.13M 26.49M 1.82B 26.65M 186M 71.82M 925M 71.4M 69.82M 2.95B | P/E 2026 * |
-1.92x | P/E 2027 * | -1.3x |
|---|---|---|---|---|---|
| Enterprise Value | 19.01M 16.47M 15.57M 14.13M 26.49M 1.82B 26.65M 186M 71.82M 925M 71.4M 69.82M 2.95B | EV / Sales 2026 * |
4.48x | EV / Sales 2027 * | 0.94x |
| Free-Float |
94.51% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: TapImmune Inc.
| 21/08/21 | Wall Street hoger gesloten | |
| 20/08/21 | Wall Street koerst af op hoger slot | |
| 20/08/21 | Wall Street richting lagere opening |
| Manager | Title | Age | Since |
|---|---|---|---|
Juan Vera
CEO | Chief Executive Officer | 46 | 01/05/2023 |
| Chief Operating Officer | 36 | 01/12/2023 | |
Patricia Allison
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Juan Vera
BRD | Director/Board Member | 46 | 17/10/2018 |
Norman Eansor
CHM | Chairman | 65 | 24/05/2022 |
Steven Elms
BRD | Director/Board Member | 62 | 06/08/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 19.01M | |
| +0.67% | +0.64% | -1.36% | +26.89% | 45.91B | |
| -0.32% | +4.61% | +43.90% | +26.98% | 44.25B | |
| -4.36% | -5.66% | +338.30% | +516.88% | 41.99B | |
| +0.46% | -0.83% | +6.38% | +73.76% | 39.58B | |
| -0.17% | -3.22% | +10.29% | +38.69% | 31.08B | |
| -0.65% | +5.14% | +25.61% | +120.17% | 17.21B | |
| +3.30% | -5.03% | - | - | 16.27B | |
| +2.28% | +7.73% | +21.69% | +38.86% | 14.96B | |
| +0.86% | +9.05% | +0.47% | -33.54% | 13.42B | |
| Average | +0.21% | +1.18% | +55.66% | +101.09% | 29.41B | |
| Weighted average by Cap. | -0.25% | +0.31% | +70.17% | +122.60% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.24M 3.68M 3.47M 3.15M 5.91M 407M 5.95M 41.48M 16.03M 206M 15.94M 15.58M 658M | 20.19M 17.49M 16.53M 15.01M 28.13M 1.94B 28.3M 197M 76.27M 982M 75.83M 74.14M 3.13B |
| Net income | -11.84M -10.26M -9.69M -8.8M -16.5M -1.14B -16.59M -116M -44.72M -576M -44.46M -43.48M -1.84B | -18.09M -15.68M -14.82M -13.45M -25.21M -1.74B -25.36M -177M -68.36M -880M -67.96M -66.45M -2.81B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
